Lundbeck ‘delivering according to expectations’

Lundbeck is performing according to plan financially, it has been stated, as the firm released its third-quarter results this week.

Revenue for the period stood at 3.264 million Danish kroner (394.434 million pounds) – representing 20 per cent growth on figures from the third-quarter of 2008.

Its total profit from operations was 784 million Danish kroner, a sum the firm states has been affected by continued high level of investments in its late-stage pipeline.

Developments during this timeframe include the Food and Drug Administration’s approval of Sabril for the treatment of refractory complex partial seizures and infantile spasms and the continued growth of Ebixa and Azilect of 17 per cent and 47 per cent respectively.

Lundbeck’s president and chief executive officer Ulf Wiinberg commented: “We are pleased to see that our [?] position is strengthened in virtually all markets and our key products continue to expand their market shares around the world.”

In other news, Lundbeck recently announced that it has launched a trial into its Friedreich’s ataxia drug Lu AA24493, which will explore the tolerability and safety of the product.